Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results